96 related articles for article (PubMed ID: 36227681)
1. Molecular interaction of cryptophycin 52 with Caspase 8 for the management of lung cancer during coronavirus outbreak : A computational study.
Leena Hussein Bajrai ; Sayed Sartaj Sohrab ; Mohammad Khalid ; Mohammad A Kamal ; Esam Ibraheem Azhar
Cell Mol Biol (Noisy-le-grand); 2022 Jun; 68(6):31-35. PubMed ID: 36227681
[TBL] [Abstract][Full Text] [Related]
2. Study of Caspase 8 Inhibition for the Management of Alzheimer's Disease: A Molecular Docking and Dynamics Simulation.
Ahmad SS; Sinha M; Ahmad K; Khalid M; Choi I
Molecules; 2020 Apr; 25(9):. PubMed ID: 32365525
[TBL] [Abstract][Full Text] [Related]
3. The novel antimicrotubule agent cryptophycin 52 (LY355703) induces apoptosis via multiple pathways in human prostate cancer cells.
Drew L; Fine RL; Do TN; Douglas GP; Petrylak DP
Clin Cancer Res; 2002 Dec; 8(12):3922-32. PubMed ID: 12473608
[TBL] [Abstract][Full Text] [Related]
4. Interaction of the antitumor compound cryptophycin-52 with tubulin.
Panda D; Ananthnarayan V; Larson G; Shih C; Jordan MA; Wilson L
Biochemistry; 2000 Nov; 39(46):14121-7. PubMed ID: 11087360
[TBL] [Abstract][Full Text] [Related]
5. Binding of the epoxide cryptophycin analog, LY355703 to albumin and its effect on in vitro antiproliferative activity.
Schultz RM; Shih C; Wood PG; Harrison SD; Ehlhardt WJ
Oncol Rep; 1998; 5(5):1089-94. PubMed ID: 9683814
[TBL] [Abstract][Full Text] [Related]
6. Preclinical anticancer activity of cryptophycin-8.
Corbett TH; Valeriote FA; Demchik L; Polin L; Panchapor C; Pugh S; White K; Knight J; Jones J; Jones L; LoRusso P; Foster B; Wiegand RA; Lisow L; Golakoti T; Heltzel CE; Ogino J; Patterson GM; Moore RE
J Exp Ther Oncol; 1996 Mar; 1(2):95-108. PubMed ID: 9414393
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer.
Edelman MJ; Gandara DR; Hausner P; Israel V; Thornton D; DeSanto J; Doyle LA
Lung Cancer; 2003 Feb; 39(2):197-9. PubMed ID: 12581573
[TBL] [Abstract][Full Text] [Related]
8. Conformational changes in tubulin upon binding cryptophycin-52 reveal its mechanism of action.
Eren E; Watts NR; Sackett DL; Wingfield PT
J Biol Chem; 2021 Oct; 297(4):101138. PubMed ID: 34461087
[TBL] [Abstract][Full Text] [Related]
9. A convergent approach to cryptophycin 52 analogues: synthesis and biological evaluation of a novel series of fragment a epoxides and chlorohydrins.
Al-Awar RS; Ray JE; Schultz RM; Andis SL; Kennedy JH; Moore RE; Liang J; Golakoti T; Subbaraju GV; Corbett TH
J Med Chem; 2003 Jul; 46(14):2985-3007. PubMed ID: 12825938
[TBL] [Abstract][Full Text] [Related]
10. Antiproliferative mechanism of action of cryptophycin-52: kinetic stabilization of microtubule dynamics by high-affinity binding to microtubule ends.
Panda D; DeLuca K; Williams D; Jordan MA; Wilson L
Proc Natl Acad Sci U S A; 1998 Aug; 95(16):9313-8. PubMed ID: 9689077
[TBL] [Abstract][Full Text] [Related]
11. Cryptophycin-55/52 based antibody-drug conjugates: Synthesis, efficacy, and mode of action studies.
Lai Q; Wu M; Wang R; Lai W; Tao Y; Lu Y; Wang Y; Yu L; Zhang R; Peng Y; Jiang X; Fu Y; Wang X; Zhang Z; Guo C; Liao W; Zhang Y; Kang T; Chen H; Yao Y; Gou L; Yang J
Eur J Med Chem; 2020 Aug; 199():112364. PubMed ID: 32402935
[TBL] [Abstract][Full Text] [Related]
12. Cryptophycin 52 and cryptophycin 55 in sequential and simultaneous combination treatment regimens in human tumor xenografts.
Teicher BA; Forler P; Menon K; Phares V; Amsrud T; Shih C
In Vivo; 2000; 14(4):471-80. PubMed ID: 10945160
[TBL] [Abstract][Full Text] [Related]
13. In vitro pharmacology of cryptophycin 52 (LY355703) in human tumor cell lines.
Wagner MM; Paul DC; Shih C; Jordan MA; Wilson L; Williams DC
Cancer Chemother Pharmacol; 1999; 43(2):115-25. PubMed ID: 9923816
[TBL] [Abstract][Full Text] [Related]
14. Development of Effective Therapeutic Molecule from Natural Sources against Coronavirus Protease.
Fadaka AO; Sibuyi NRS; Martin DR; Klein A; Madiehe A; Meyer M
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502340
[TBL] [Abstract][Full Text] [Related]
15. Enantioselective synthesis of (+)-cryptophycin 52 (LY355703), a potent antimitotic antitumor agent.
Ghosh AK; Swanson L
J Org Chem; 2003 Dec; 68(25):9823-6. PubMed ID: 14656116
[TBL] [Abstract][Full Text] [Related]
16. Structure-based virtual screening, in silico docking, ADME properties prediction and molecular dynamics studies for the identification of potential inhibitors against SARS-CoV-2 M
Mohan A; Rendine N; Mohammed MKS; Jeeva A; Ji HF; Talluri VR
Mol Divers; 2022 Jun; 26(3):1645-1661. PubMed ID: 34480682
[TBL] [Abstract][Full Text] [Related]
17. Identification of anti-filarial leads against aspartate semialdehyde dehydrogenase of Wolbachia endosymbiont of Brugia malayi: combined molecular docking and molecular dynamics approaches.
Amala M; Rajamanikandan S; Prabhu D; Surekha K; Jeyakanthan J
J Biomol Struct Dyn; 2019 Feb; 37(2):394-410. PubMed ID: 29334340
[TBL] [Abstract][Full Text] [Related]
18. Three new cryptophycins from Nostoc sp. GSV 224.
Subbaraju GV; Golakoti T; Patterson GM; Moore RE
J Nat Prod; 1997 Mar; 60(3):302-5. PubMed ID: 9090872
[TBL] [Abstract][Full Text] [Related]
19. Targeting protein tyrosine phosphatase to unravel possible inhibitors for Streptococcus pneumoniae using molecular docking, molecular dynamics simulations coupled with free energy calculations.
Zaman Z; Khan S; Nouroz F; Farooq U; Urooj A
Life Sci; 2021 Jan; 264():118621. PubMed ID: 33164832
[TBL] [Abstract][Full Text] [Related]
20.
Maurya AK; Mishra N
J Biomol Struct Dyn; 2021 Nov; 39(18):7306-7321. PubMed ID: 32835632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
